The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: A double-blind, placebo-controlled, crossover study in normal subjects

British Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2002, Pages 38-44

  Tfelt Hansen, Peer ^a,c   Seidelin, Kaj ^a   Stepanavage, Michael ^b   Lines, Christopher ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Ergotamine; Migraine; Peripheral arteries; Rizatriptan

Indexed keywords

ERGOTAMINE TARTRATE; RIZATRIPTAN;

ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALAISE; MALE; MEASUREMENT; NAUSEA; NORMAL HUMAN; PARESTHESIA; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RESTLESSNESS; SWEATING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; THROAT DISEASE; VERTIGO; VOMITING;

ADULT; ARTERIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ERGOTAMINE; HEART RATE; HUMANS; MALE; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0036965792     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01403.x     Document Type: Article

References (28)

1. 1B/1D receptor agonists, in the acute treatment of migraine. In The Headaches, eds Olesen, J, Tfelt-Hansen, P, Welch, KMA. 2nd edn. New York, Lippincott, Williams & Wilkins, 2000; 411-438.
2. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of their pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259-1287.
3. Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. Contractile 5-HT1B receptors in human cerebral arteries. pharmacological characterization and localization with immunochemistry. Br J Pharmacol 1999; 128: 1133-1140.
4. Hamel E. Serotonin receptors. Relevance to migraine pathogenesis and treatment. In The Headaches, eds Olesen, J, Tfelt-Hansen, P, Welch, KMA., 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000: 133-139.
5. Humphrey PPA, Apperley E, Feniuk W, Perren MJ. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications, eds Saxena, PR, Wallis, DI, Wouters, W, Bevan, P. Dordrecht: Kluwer Academic Publishers, 1990; 416-431.
6. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-446.
7. Nilsson F, Nilsson T, Edvinsson L, Björkman S, Nordström C-H. Effects of dihydroergotamine and sumatriptan on isolated human cerebral and peripheral arteries and veins. Acta Anaesthesiol Scand 1997; 41: 1257-1262.
8. 2 receptor activation. Eur J Pharmacol 1989; 161: 91-94.
9. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijsen EJ, Bos E, Saxena PR. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993; 239: 203-210.
10. Jansen I, Olesen J, Edvinsson L. 5-hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. Acta Physiol Scand 1993; 147: 141-150.
11. 1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000; 68: 418-426.
12. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In The Headaches, eds Olesen, J, Tfelt-Hansen, P, Welch, KMA., 2nd edn. New York: Lippincott, Williams & Wilkins, 2000; 399-409.
13. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine - European Consensus. Brain 2000; 123: 9-18.
14. Peroutka SJ. Drugs effective in the therapy of migraine. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics, eds Hardman JG, Limbird, LE, Molinoff, PB, Ruddon, RW, Gilman, AG., 9th edn. New York: McGraw-Hill Companies, 1995; 487-502.
15. Tfelt-Hansen P, Eickhoff JH, Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients. Methodological aspects and time effect curve. Acta Pharmacol Toxicol 1980; 47: 151-156.
16. Tfelt-Hansen P, Sperling B, Winter PD. Transient additional effect of sumatriptan on ergotamine-induced constriction of peripheral arteries in man. Clin Pharmacol Ther 1992; 51: 149 (Abstract).
17. Dixon RM, Meire HB, Evans DH, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 1997; 17: 639-646.
18. Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol 1986; 59(Suppl 3): 1-30.
19. Tfelt-Hansen P, Manniche PM. Dose-response curve for the ergotamine-induced decrease of peripheral systolic blood pressure in man. Acta Pharmacol Toxicol 1984; 55: 238-241.
20. Tfelt-Hansen P, Olesen J. Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients. Acta Pharmacol Toxicol 1981; 48: 69-72.
21. Bülow P, Ibraheem JJ, Paalzow G, Tfelt-Hansen P. Comparison of pharmacodynamic effects and plasma levels of oral and rectal ergotamine. Cephalalgia 1986; 6: 107-111.
22. Tfelt-Hansen P, Palzow L. Intramuscular ergotamine, plasma levels and dynamic activity. Clin Pharmacol Ther 1985; 37: 29-35.
23. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401-405.
24. Merck & Co. Inc. Maxalt (rizatriptan benzoate). Physicians Disk Reference. Medical Economic Company, Montvale, NJ. 2000, (54th edn): 1822-1826.
25. Thomsen LL, Olesen J. The autonomic nervous system and the regulation of arterial tone in migraine. Clin Auton Res 1995; 5: 243-250.
26. Galer BS, Lipton RB, Solomon S, Newmann LC, Spierings ELH. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache 1991; 31: 446-451.
27. 1B/1D agonists - is there a cause for concern? Cephalalgia 1998; 18: 539-545.
28. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30.